Cargando…
Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-effects meta-analysis of double-blind, randomized, placebo-cont...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240021/ https://www.ncbi.nlm.nih.gov/pubmed/35764619 http://dx.doi.org/10.1038/s41398-022-02026-5 |
_version_ | 1784737445828362240 |
---|---|
author | Kishi, Taro Sakuma, Kenji Iwata, Nakao |
author_facet | Kishi, Taro Sakuma, Kenji Iwata, Nakao |
author_sort | Kishi, Taro |
collection | PubMed |
description | It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-effects meta-analysis of double-blind, randomized, placebo-controlled trials. The primary outcome was change in overall symptoms as measured using standardized rating scales. Other outcomes were response to treatment; improvement in anxiety-related scales scores, depression-related scale scores, Clinical Global Impression Severity Scale (CGI-S) scores, and Sheehan Disability Scale (SDS) scores; all-cause discontinuation; and individual adverse events. We calculated the standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes with 95% confidence intervals. We reviewed 17 studies (n = 629, 72.62% female; duration = 2–20 weeks; mean age = 30.47 years) of MMs: eicosapentaenoic acid (K = 1), folic acid (K = 1), lithium (K = 1), N-acetylcysteine (K = 10), inositol (K = 3), and silymarin (K = 1). MMs outperformed placebo in overall improvement in symptoms (p < 0.01) and in improving anxiety-related scale scores (p = 0.05). Subgroup analysis of individual MMs revealed that although overall symptoms were better improved by N-acetylcysteine (p < 0.01) and lithium (p = 0.04), no MMs outperformed placebo in terms of improving anxiety-related scale scores. Neither pooled nor individual MMs outperformed placebo in improving response to treatment, depression-related scale scores, CGI-S scores, SDS scores, or all-cause discontinuation. N-acetylcysteine was no more associated with a higher incidence of individual adverse events including gastrointestinal symptoms, than placebo. In conclusion, N-acetylcysteine was beneficial in the treatment of obsessive–compulsive and related disorders. However, further study with larger samples is necessary to confirm this finding. |
format | Online Article Text |
id | pubmed-9240021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92400212022-06-30 Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis Kishi, Taro Sakuma, Kenji Iwata, Nakao Transl Psychiatry Article It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-effects meta-analysis of double-blind, randomized, placebo-controlled trials. The primary outcome was change in overall symptoms as measured using standardized rating scales. Other outcomes were response to treatment; improvement in anxiety-related scales scores, depression-related scale scores, Clinical Global Impression Severity Scale (CGI-S) scores, and Sheehan Disability Scale (SDS) scores; all-cause discontinuation; and individual adverse events. We calculated the standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes with 95% confidence intervals. We reviewed 17 studies (n = 629, 72.62% female; duration = 2–20 weeks; mean age = 30.47 years) of MMs: eicosapentaenoic acid (K = 1), folic acid (K = 1), lithium (K = 1), N-acetylcysteine (K = 10), inositol (K = 3), and silymarin (K = 1). MMs outperformed placebo in overall improvement in symptoms (p < 0.01) and in improving anxiety-related scale scores (p = 0.05). Subgroup analysis of individual MMs revealed that although overall symptoms were better improved by N-acetylcysteine (p < 0.01) and lithium (p = 0.04), no MMs outperformed placebo in terms of improving anxiety-related scale scores. Neither pooled nor individual MMs outperformed placebo in improving response to treatment, depression-related scale scores, CGI-S scores, SDS scores, or all-cause discontinuation. N-acetylcysteine was no more associated with a higher incidence of individual adverse events including gastrointestinal symptoms, than placebo. In conclusion, N-acetylcysteine was beneficial in the treatment of obsessive–compulsive and related disorders. However, further study with larger samples is necessary to confirm this finding. Nature Publishing Group UK 2022-06-28 /pmc/articles/PMC9240021/ /pubmed/35764619 http://dx.doi.org/10.1038/s41398-022-02026-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kishi, Taro Sakuma, Kenji Iwata, Nakao Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
title | Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
title_full | Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
title_fullStr | Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
title_full_unstemmed | Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
title_short | Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
title_sort | mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240021/ https://www.ncbi.nlm.nih.gov/pubmed/35764619 http://dx.doi.org/10.1038/s41398-022-02026-5 |
work_keys_str_mv | AT kishitaro mitochondrialmodulatorsforobsessivecompulsiveandrelateddisordersasystematicreviewandmetaanalysis AT sakumakenji mitochondrialmodulatorsforobsessivecompulsiveandrelateddisordersasystematicreviewandmetaanalysis AT iwatanakao mitochondrialmodulatorsforobsessivecompulsiveandrelateddisordersasystematicreviewandmetaanalysis |